Novartis AG’s exit from its listed Indian subsidiary highlights a growing trend of "Big Pharma" companies divesting from the hyper-competitive Indian market.

Feb 4 (Reuters) - The S&P 500 opened largely flat and the Dow marginally higher on Wednesday, following upbeat results from Eli Lilly and Super Micro Computer, while investors avoided big bets on ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Pennsylvania's Lehigh Valley that will help make its next-generation obesity drugs. That includes a closely watched ...

Analysts on Wall Street project that Eli Lilly (LLY) will announce quarterly earnings of $6.99 per share in its forthcoming report, representing an increase of 31.4% year over year. Revenues are ...

For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. In early 2024, the Big Pharma debuted a pair of unbranded shorts entitled “Big ...

How Evangeline Lilly is doing now. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. In May 2025, Evangeline Lilly posted on her Substack that she ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making ...

Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over ...

Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space of oral obesity therapies. The latest partnership will see Lilly pass ...